Prolonged survival in patients with hand-foot skin reaction secondary to cooperative sorafenib treatment

BACKGROUND Sorafenib is an oral drug that prolongs overall survival(OS)in patients with hepatocellular carcinoma.Adverse events,including hand-foot skin reaction(HFSR),lead to permanent sorafenib discontinuation.AIM To clarify the association between interventions for adverse events and patient prognosis.METHODS We performed a retrospective,multicenter study of patients treated with sorafenib monotherapy between May 2009 and March 2018.We developed a mutual cooperation system that was initiated at the start of sorafenib treatment to effectively manage adverse events.The mutual cooperation system entailed patients receiving consultations during which pharmacists provided accurate information about sorafenib to alleviate the fear and anxiety related to adverse events.We stratified the patients into three groups:Group A,patients without HFSR but with pharmacist intervention;Group B,patients with HFSR and pharmacist interventions unreported to oncologists(nonmutual cooperation system);and Group C,patients with HFSR and pharmacist interventions known to oncologists(mutual cooperation system).OS and time to treatment failure(TTF)were evaluated using the Kaplan-Meier method.RESULTS We enrolled 134 patients(Group A,n=41;Group B,n=30;Group C,n=63).The median OS was significantly different between Groups A and C(6.2 vs 13.9 mo,p<0.01)but not between Groups A and B(6.2 vs 7.7 mo,P=0.62).Group A vs Group C was an independent OS predictor(HR,0.41;95%CI:0.25-0.66;P<0.01).In Group B alone,TTF was significantly lower and the nonadherence rate was higher(P<0.01).In addition,the Spearman’s rank correlation coefficients between OS and TTF in each group were 0.41(Group A;P<0.01),0.13(Group B;P=0.51),and 0.58(Group C;P<0.01).There was a highly significant correlation between OS and TTF in Group C.However,there was no correlation between OS and TTF in Group B.CONCLUSION The mutual cooperation system increased treatment duration and improved prognosis in patients with HFSR.Future prospective studies(e.g.,randomized controlled trials)and improved adherence could help prevent OS underestimation.